STAT

Opinion: Covid-19 is reshaping the world of bioscience publishing

The enhanced use of preprints, the evolution of "standard" journals, and effective use of social media will all be required for bioscience publishing to adapt to a changing and challenging…
A transmission electron micrograph of a SARS-CoV-2 virus particle, isolated from a patient

The Covid-19 pandemic is rapidly changing our lives in previously unimaginable ways and forcing us to view many behaviors in a new light. That is certainly the case for bioscience publishing, which has already undergone significant change in the digital era.

These changes are accelerating in real time in response to the epidemic and the need it created to rapidly disseminate information about the biology of the virus, the clinical features of the infection it causes, and possibilities for prevention and therapy. As is so often the case, necessity accelerates transformative change.

Scientific progress depends on effective transmission of research results to the scientific community, enabling discoveries to be assessed and extended. Once the domain of physical journals collected and

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks